Of 465 patients with nonmetastatic MIBC enrolled in 6 prospective RTOG clinical trials of trimodality therapy, 168 patients had tumor tissues analyzable for MRE11 expression, of which 135 (80.4%) were analyzable for MRE11 NC ratio (Table 1). The gene discussed is MRE11; the disease is neoplasm.